Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (141-150 of 280) with videos related to

Pageof 28
Sort By:
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
Cardiovascular Research|February 12, 2016
miR-21 promotes fibrosis in an acute cardiac allograft transplantation modelShashi Kumar Gupta, Ryo Itagaki, Xiang Zheng, et al.
Journal for Immunotherapy of Cancer|December 22, 2023
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemiaShifaa M Abdin, Daniela Paasch, Arnold Kloos, et al.
Leukemia|September 19, 2020
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysisBadder Kattih, Amir Shirvani, Piroska Klement, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Pageof 28

Showing results (141-150 of 280) with videos related to

Sort By:
Pageof 28
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
The New England Journal of Medicine|April 20, 2022
Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid LeukemiaPau Montesinos, Christian Recher, Susana Vives, et al.
Annals of Hematology|May 12, 2021
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Transplantation and Cellular Therapy|October 11, 2020
Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic LeukemiaNico Gagelmann, Rashit Bogdanov, Friedrich Stölzel, et al.
Cardiovascular Research|February 12, 2016
miR-21 promotes fibrosis in an acute cardiac allograft transplantation modelShashi Kumar Gupta, Ryo Itagaki, Xiang Zheng, et al.
Journal for Immunotherapy of Cancer|December 22, 2023
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemiaShifaa M Abdin, Daniela Paasch, Arnold Kloos, et al.
Leukemia|September 19, 2020
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysisBadder Kattih, Amir Shirvani, Piroska Klement, et al.
Annals of Hematology|March 19, 2021
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trialMichael Heuser, B Douglas Smith, Walter Fiedler, et al.
Leukemia|October 7, 2025
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trialInga Hund, Maria Elena Hess, Geoffroy Andrieux, et al.
Pageof 28